WO2003057822A3 - Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends - Google Patents
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends Download PDFInfo
- Publication number
- WO2003057822A3 WO2003057822A3 PCT/US2002/034247 US0234247W WO03057822A3 WO 2003057822 A3 WO2003057822 A3 WO 2003057822A3 US 0234247 W US0234247 W US 0234247W WO 03057822 A3 WO03057822 A3 WO 03057822A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oligonucleotide
- modulation
- based compounds
- oligonucleotides
- immunostimulatory properties
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3183—Diol linkers, e.g. glycols or propanediols
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/52—Physical structure branched
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2463798A CA2463798C (en) | 2001-10-24 | 2002-10-24 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
JP2003558124A JP5005878B2 (en) | 2001-10-24 | 2002-10-24 | Regulation of immunostimulation of oligonucleotide compounds by optimal display of the 5 'end |
AU2002365141A AU2002365141C1 (en) | 2001-10-24 | 2002-10-24 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
KR1020047006160A KR100945104B1 (en) | 2001-10-24 | 2002-10-24 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34476701P | 2001-10-24 | 2001-10-24 | |
US60/344,767 | 2001-10-24 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2003057822A2 WO2003057822A2 (en) | 2003-07-17 |
WO2003057822A3 true WO2003057822A3 (en) | 2004-02-26 |
WO2003057822A9 WO2003057822A9 (en) | 2004-07-01 |
Family
ID=23351942
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/033756 WO2003035836A2 (en) | 2001-10-24 | 2002-10-22 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
PCT/US2002/034247 WO2003057822A2 (en) | 2001-10-24 | 2002-10-24 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/033756 WO2003035836A2 (en) | 2001-10-24 | 2002-10-22 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP5005878B2 (en) |
KR (1) | KR100945104B1 (en) |
AU (1) | AU2002365141C1 (en) |
CA (1) | CA2463798C (en) |
WO (2) | WO2003035836A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7723500B2 (en) | 1994-07-15 | 2010-05-25 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US8188254B2 (en) | 2003-10-30 | 2012-05-29 | Coley Pharmaceutical Gmbh | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
US9028845B2 (en) | 2001-06-21 | 2015-05-12 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same-IV |
Families Citing this family (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7276489B2 (en) * | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
EP1393745A1 (en) * | 2002-07-29 | 2004-03-03 | Hybridon, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5'ends |
AR040996A1 (en) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | IMMUNE STIMULATING NUCLEIC ACIDS |
BRPI0315228A8 (en) | 2002-10-11 | 2018-04-03 | Chiron Srl | Polypeptide vaccines for broad protection against hypervirulent meningococcal strains |
EP2241325B1 (en) | 2002-10-29 | 2012-02-08 | Coley Pharmaceutical Group, Inc. | Use of CPG oligonucleotides in the treatment of hepatitis C virus infection |
JP2006512927A (en) | 2002-12-11 | 2006-04-20 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 5 'CPG nucleic acids and methods of use thereof |
JP2006516099A (en) * | 2002-12-23 | 2006-06-22 | ダイナバックス テクノロジーズ コーポレイション | Branched immunomodulatory compounds and methods of using the compounds |
EP2172213B1 (en) | 2003-01-30 | 2013-04-03 | Novartis AG | Injectable vaccines against multiple meningococcal serogroups |
US7354907B2 (en) * | 2003-02-07 | 2008-04-08 | Idera Pharmaceuticals, Inc. | Short immunomodulatory oligonucleotides |
NZ543467A (en) | 2003-04-10 | 2008-07-31 | Novartis Vaccines & Diagnostic | The severe acute respiratory syndrome coronavirus |
MXPA05012421A (en) | 2003-05-16 | 2006-02-22 | Hybridon Inc | Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents. |
JP2007531699A (en) * | 2003-07-15 | 2007-11-08 | イデラ ファーマシューティカルズ インコーポレイテッド | Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and / or immunomeric compounds in combination with cytokines and / or chemotherapeutic agents or radiation therapy |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
WO2005032583A2 (en) | 2003-10-02 | 2005-04-14 | Chiron Srl | Liquid vaccines for multiple meningococcal serogroups |
KR101138131B1 (en) * | 2003-12-08 | 2012-04-23 | 이데라 파마슈티칼즈, 인코포레이티드 | Modulation of immunostimulatory properties by small oligonucleotide-based compounds |
JP4817599B2 (en) * | 2003-12-25 | 2011-11-16 | 独立行政法人科学技術振興機構 | Immune activity enhancer and method for enhancing immune activity using the same |
AU2005216075B2 (en) * | 2004-02-20 | 2011-03-10 | Idera Pharmaceuticals, Inc. | Potent mucosal immune response induced by modified immunomodulatory oligonucleotides |
EP1722815A1 (en) | 2004-03-09 | 2006-11-22 | Chiron Corporation | Influenza virus vaccines |
PL1740217T3 (en) | 2004-04-30 | 2012-03-30 | Novartis Ag | Meningococcal conjugate vaccination |
GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
GB0409745D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
JP4896021B2 (en) | 2004-05-21 | 2012-03-14 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | Alphavirus vector for respiratory pathogen vaccine |
WO2006080946A2 (en) * | 2004-06-08 | 2006-08-03 | Coley Pharmaceutical Gmbh | Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist |
KR20070028537A (en) * | 2004-06-15 | 2007-03-12 | 이데라 파마슈티칼즈, 인코포레이티드 | Immunostimulatory oligonucleotide multimers |
US20060165716A1 (en) | 2004-07-29 | 2006-07-27 | Telford John L | Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae |
MY159370A (en) | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
WO2006091517A2 (en) | 2005-02-18 | 2006-08-31 | Novartis Vaccines And Diagnostics Inc. | Immunogens from uropathogenic escherichia coli |
PL2351772T3 (en) | 2005-02-18 | 2017-01-31 | Glaxosmithkline Biologicals Sa | Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli |
JP2008536515A (en) | 2005-04-18 | 2008-09-11 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | Expression of hepatitis B virus surface antigen for vaccine preparation |
EP2614709A1 (en) | 2005-07-18 | 2013-07-17 | Novartis AG | Small animal model for HCV replication |
EP2357000A1 (en) | 2005-10-18 | 2011-08-17 | Novartis Vaccines and Diagnostics, Inc. | Mucosal and systemic immunizations with alphavirus replicon particles |
ES2420829T3 (en) | 2005-11-04 | 2013-08-27 | Novartis Vaccines And Diagnostics S.R.L. | Vaccines adjuvant with non-virion antigen prepared from influenza viruses grown in cell culture |
DK1951299T3 (en) | 2005-11-04 | 2012-04-02 | Novartis Vaccines & Diagnostic | Influenza vaccines containing combinations of particulate adjuvants and immune enhancers |
EP2377552A3 (en) | 2005-11-04 | 2013-05-15 | Novartis Vaccines and Diagnostics S.r.l. | Influenza vaccines with reduced amount of emulsion adjuvant |
US20110180430A1 (en) | 2005-11-04 | 2011-07-28 | Novartis Vaccines And Diagnostics Srl | Adjuvanted influenza vaccines including cytokine-inducing agents |
JP5184366B2 (en) * | 2005-11-07 | 2013-04-17 | イデラ ファーマシューティカルズ インコーポレイテッド | Immunostimulatory properties of oligonucleotide-based compounds, including modified immunostimulatory dinucleotides |
JP2009514525A (en) * | 2005-11-07 | 2009-04-09 | イデラ ファーマシューティカルズ インコーポレイテッド | Immunostimulatory properties of oligonucleotide-based compounds, including modified immunostimulatory dinucleotides |
CA2630220C (en) | 2005-11-22 | 2020-10-13 | Doris Coit | Norovirus and sapovirus antigens |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
ES2707499T3 (en) | 2005-12-22 | 2019-04-03 | Glaxosmithkline Biologicals Sa | Pneumococcal polysaccharide conjugate vaccine |
NZ570106A (en) | 2006-01-27 | 2012-04-27 | Novartis Vaccines & Diagnostic | Influenza vaccines containing hemagglutinin and matrix proteins |
ATE539079T1 (en) | 2006-03-23 | 2012-01-15 | Novartis Ag | IMIDAZOCHINOXALINE COMPOUNDS AS IMMUNE MODULATORS |
EP2382987A1 (en) | 2006-03-24 | 2011-11-02 | Novartis Vaccines and Diagnostics GmbH | Storage of influenza vaccines without refrigeration |
EP1998802A2 (en) | 2006-03-30 | 2008-12-10 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
US20100285062A1 (en) | 2006-03-31 | 2010-11-11 | Novartis Ag | Combined mucosal and parenteral immunization against hiv |
EP2054431B1 (en) | 2006-06-09 | 2011-08-31 | Novartis AG | Conformers of bacterial adhesins |
GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
JP2010507361A (en) | 2006-07-31 | 2010-03-11 | キュアバック ゲーエムベーハー | Specifically, a nucleic acid represented by the general formula (I): GlXmGn or the general formula (II): ClXmCn as an immunostimulant / adjuvant |
AU2007285484B2 (en) | 2006-08-16 | 2013-05-02 | Novartis Ag | Immunogens from uropathogenic Escherichia coli |
JP5954921B2 (en) | 2006-09-11 | 2016-07-20 | ノバルティス アーゲー | Production of influenza virus vaccine without eggs |
US8110407B2 (en) | 2006-09-14 | 2012-02-07 | Konica Minolta Medical & Graphic, Inc. | Fluorescent semiconductor microparticle assembly, fluorescent labeling agent assembly for biological substance, and bioimaging method and biological substance analysis method using the assemblies |
KR101251707B1 (en) | 2006-09-27 | 2013-04-11 | 콜리 파마슈티칼 게엠베하 | CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity |
US20110045022A1 (en) | 2006-12-06 | 2011-02-24 | Theodore Tsai | Vaccines including antigen from four strains of influenza virus |
GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
WO2008142133A1 (en) | 2007-05-24 | 2008-11-27 | Glaxosmithkline Biologicals S.A | Lyophilised antigen composition |
RS54349B1 (en) | 2007-06-26 | 2016-02-29 | Glaxosmithkline Biologicals S.A. | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
EP2185191B1 (en) | 2007-06-27 | 2012-09-12 | Novartis AG | Low-additive influenza vaccines |
GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
ES2561483T3 (en) | 2007-09-12 | 2016-02-26 | Glaxosmithkline Biologicals Sa | GAS57 mutant antigens and GAS57 antibodies |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
BRPI0821240B8 (en) | 2007-12-21 | 2022-10-04 | Novartis Ag | mutant forms of streptolysin o |
HUE025027T2 (en) | 2008-01-31 | 2016-07-28 | Curevac Gmbh | NUCLEIC ACIDS COMPRISING FORMULA (NuGiXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS |
EP2245048B1 (en) | 2008-02-21 | 2014-12-31 | Novartis AG | Meningococcal fhbp polypeptides |
EP2268309B1 (en) | 2008-03-18 | 2015-01-21 | Novartis AG | Improvements in preparation of influenza virus vaccine antigens |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
US8853177B2 (en) * | 2008-10-06 | 2014-10-07 | Idera Pharmaceuticals, Inc. | Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto |
NZ594029A (en) | 2009-01-12 | 2014-01-31 | Novartis Ag | Cna_b domain antigens in vaccines against gram positive bacteria |
CA2754618A1 (en) | 2009-03-06 | 2010-09-10 | Novartis Ag | Chlamydia antigens |
AU2010238255B2 (en) | 2009-04-14 | 2014-10-16 | Novartis Ag | Compositions for immunising against Staphylococcus aureus |
CN102802665B (en) | 2009-06-15 | 2015-11-25 | 新加坡国立大学 | Influenza vaccines, compositions and using method |
MX2012000395A (en) | 2009-07-07 | 2012-02-28 | Novartis Ag | Conserved escherichia coli immunogens. |
EP3178490B1 (en) | 2009-07-15 | 2022-04-20 | GlaxoSmithKline Biologicals S.A. | Rsv f protein compositions and methods for making same |
CA2768343A1 (en) | 2009-07-16 | 2011-01-20 | Novartis Ag | Detoxified escherichia coli immunogens |
GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
CN102596240B (en) | 2009-08-27 | 2015-02-04 | 诺华股份有限公司 | Hybrid polypeptides including meningococcal fHBP sequences |
CN104673795A (en) * | 2009-08-27 | 2015-06-03 | 艾德拉药物股份有限公司 | Compositions for inhibiting gene expression and uses thereof |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
US20120237536A1 (en) | 2009-09-10 | 2012-09-20 | Novartis | Combination vaccines against respiratory tract diseases |
GB0917003D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Purification of bacterial vesicles |
GB0917002D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Improved shigella blebs |
WO2011039631A2 (en) | 2009-09-30 | 2011-04-07 | Novartis Ag | Expression of meningococcal fhbp polypeptides |
BR112012009014B8 (en) | 2009-09-30 | 2022-10-04 | Novartis Ag | PROCESS FOR PREPARING S. AUREUS CAPSULAR POLYSACCHARIDE CONJUGATE TYPE 5 OR TYPE 8 AND CRM197 TRANSPORT MOLECULE, CONJUGATE AND IMMUNOGENIC COMPOSITION |
GB0918392D0 (en) | 2009-10-20 | 2009-12-02 | Novartis Ag | Diagnostic and therapeutic methods |
MX2012004850A (en) | 2009-10-27 | 2012-05-22 | Novartis Ag | Modified meningococcal fhbp polypeptides. |
GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
US9173954B2 (en) | 2009-12-30 | 2015-11-03 | Glaxosmithkline Biologicals Sa | Polysaccharide immunogens conjugated to E. coli carrier proteins |
GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
GB201003924D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Immunogenic composition |
GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
EP2556151A1 (en) | 2010-04-07 | 2013-02-13 | Novartis AG | Method for generating a parvovirus b19 virus-like particle |
WO2011130379A1 (en) | 2010-04-13 | 2011-10-20 | Novartis Ag | Benzonapthyridine compositions and uses thereof |
EP2575988A1 (en) | 2010-05-28 | 2013-04-10 | Tetris Online, Inc. | Interactive hybrid asynchronous computer game infrastructure |
GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
WO2012006293A1 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Norovirus derived immunogenic compositions and methods |
BR112013002298A2 (en) | 2010-07-30 | 2016-05-24 | Curevac Gmbh | nucleic acid complexation with disulfide crosslinked cationic components for transfection and immune stimulation. |
GB201101665D0 (en) | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
GB201017519D0 (en) | 2010-10-15 | 2010-12-01 | Novartis Vaccines Inst For Global Health S R L | Vaccines |
WO2012072769A1 (en) | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations |
GB201021867D0 (en) | 2010-12-23 | 2011-02-02 | Mologen Ag | Non-coding immunomodulatory DNA construct |
WO2012085668A2 (en) | 2010-12-24 | 2012-06-28 | Novartis Ag | Compounds |
WO2012103361A1 (en) | 2011-01-26 | 2012-08-02 | Novartis Ag | Rsv immunization regimen |
TW201302779A (en) | 2011-04-13 | 2013-01-16 | Glaxosmithkline Biolog Sa | Fusion proteins & combination vaccines |
CN103842374A (en) | 2011-05-13 | 2014-06-04 | 诺华股份有限公司 | Pre-fusion rsv f antigens |
CA2840989A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
US11058762B2 (en) | 2011-07-06 | 2021-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic compositions and uses thereof |
US10030052B2 (en) | 2011-07-25 | 2018-07-24 | Glaxosmithkline Biologicals Sa | Parvovirus Vp1 unique region polypeptides and compositions thereof |
ES2732708T3 (en) | 2011-09-14 | 2019-11-25 | Glaxosmithkline Biologicals Sa | Manufacturing procedures of saccharide-protein glucoconjugates |
EP2776069A1 (en) | 2011-11-07 | 2014-09-17 | Novartis AG | Carrier molecule comprising a spr0096 and a spr2021 antigen |
WO2013108272A2 (en) | 2012-01-20 | 2013-07-25 | International Centre For Genetic Engineering And Biotechnology | Blood stage malaria vaccine |
WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
CA2874210A1 (en) | 2012-05-22 | 2013-11-28 | Novartis Ag | Meningococcus serogroup x conjugate |
EP2869842A1 (en) | 2012-07-06 | 2015-05-13 | Novartis AG | Immunogenic compositions and uses thereof |
EP2897635A1 (en) | 2012-09-18 | 2015-07-29 | Novartis AG | Outer membrane vesicles |
CN105307684A (en) | 2012-10-02 | 2016-02-03 | 葛兰素史密丝克莱恩生物有限公司 | Nonlinear saccharide conjugates |
CN104582718B (en) | 2012-10-03 | 2017-10-24 | 诺华股份有限公司 | Immunogenic composition |
BR112015016420B1 (en) * | 2013-01-08 | 2022-12-06 | Idera Pharmaceuticals, Inc | IMMUNORREGULATORY OLIGONUCLEOTIDE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE OF THE IRO COMPOUND OR PHARMACEUTICAL COMPOSITION |
KR20160044566A (en) | 2013-08-21 | 2016-04-25 | 큐어백 아게 | Respiratory syncytial virus (RSV) vaccine |
EP2870974A1 (en) | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
TW201620927A (en) | 2014-02-24 | 2016-06-16 | 葛蘭素史密斯克藍生物品公司 | USPA2 protein constructs and uses thereof |
RS59971B1 (en) | 2014-03-26 | 2020-03-31 | Glaxosmithkline Biologicals Sa | Mutant staphylococcal antigens |
EP3129050A2 (en) | 2014-04-01 | 2017-02-15 | CureVac AG | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
AU2015359503B2 (en) | 2014-12-10 | 2019-05-09 | Glaxosmithkline Biologicals Sa | Method of treatment |
JP6698069B2 (en) * | 2015-03-20 | 2020-05-27 | 国立研究開発法人医薬基盤・健康・栄養研究所 | CpG spacer oligonucleotide-containing complex having immunostimulatory activity and use thereof |
US11013795B2 (en) | 2015-06-26 | 2021-05-25 | Seqirus UK Limited | Antigenically matched influenza vaccines |
LU92821B1 (en) | 2015-09-09 | 2017-03-20 | Mologen Ag | Combination comprising immunostimulatory oligonucleotides |
GB2542425A (en) | 2015-09-21 | 2017-03-22 | Mologen Ag | Means for the treatment of HIV |
WO2018178264A1 (en) | 2017-03-31 | 2018-10-04 | Glaxosmithkline Intellectual Property Development Limited | Immunogenic composition, use and method of treatment |
WO2018178265A1 (en) | 2017-03-31 | 2018-10-04 | Glaxosmithkline Intellectual Property Development Limited | Immunogenic composition, use and method of treatment |
US11723966B2 (en) | 2017-08-14 | 2023-08-15 | Glaxosmithkline Biologicals Sa | Methods of boosting immune responses |
WO2020212461A1 (en) | 2019-04-18 | 2020-10-22 | Glaxosmithkline Biologicals Sa | Antigen binding proteins and assays |
WO2023201109A1 (en) | 2022-04-15 | 2023-10-19 | Yale University | Exatecan formulation |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5856462A (en) * | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
US6172208B1 (en) * | 1992-07-06 | 2001-01-09 | Genzyme Corporation | Oligonucleotides modified with conjugate groups |
US6218371B1 (en) * | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1215994A (en) * | 1996-02-15 | 1999-05-05 | 国家健康学会 | Rnase L activators and antisense oligonucleotides effective to treat RSV infections |
EP1322656B1 (en) * | 2000-09-26 | 2008-01-16 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
US20030199466A1 (en) * | 2001-06-21 | 2003-10-23 | Fearon Karen L. | Chimeric immunomodulatory compounds and methods of using the same - ll |
-
2002
- 2002-10-22 WO PCT/US2002/033756 patent/WO2003035836A2/en not_active Application Discontinuation
- 2002-10-24 CA CA2463798A patent/CA2463798C/en not_active Expired - Lifetime
- 2002-10-24 JP JP2003558124A patent/JP5005878B2/en not_active Expired - Lifetime
- 2002-10-24 KR KR1020047006160A patent/KR100945104B1/en active IP Right Grant
- 2002-10-24 WO PCT/US2002/034247 patent/WO2003057822A2/en active IP Right Grant
- 2002-10-24 AU AU2002365141A patent/AU2002365141C1/en not_active Expired
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6172208B1 (en) * | 1992-07-06 | 2001-01-09 | Genzyme Corporation | Oligonucleotides modified with conjugate groups |
US5856462A (en) * | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
US6218371B1 (en) * | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7723500B2 (en) | 1994-07-15 | 2010-05-25 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US9028845B2 (en) | 2001-06-21 | 2015-05-12 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same-IV |
US8188254B2 (en) | 2003-10-30 | 2012-05-29 | Coley Pharmaceutical Gmbh | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
Also Published As
Publication number | Publication date |
---|---|
JP5005878B2 (en) | 2012-08-22 |
AU2002365141B2 (en) | 2007-06-14 |
WO2003057822A9 (en) | 2004-07-01 |
AU2002365141A1 (en) | 2003-07-24 |
WO2003035836A2 (en) | 2003-05-01 |
WO2003057822A2 (en) | 2003-07-17 |
CA2463798A1 (en) | 2003-07-17 |
KR100945104B1 (en) | 2010-03-02 |
JP2005518402A (en) | 2005-06-23 |
AU2002365141C1 (en) | 2008-07-24 |
KR20040047969A (en) | 2004-06-05 |
CA2463798C (en) | 2015-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003057822A3 (en) | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends | |
WO2004064782A3 (en) | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides | |
EP2371956A3 (en) | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides | |
WO2001055370A3 (en) | MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES | |
WO2003086280A3 (en) | Immunostimulatory g,u-containing oligoribonucleotides | |
WO2001012804A3 (en) | MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES | |
WO2001083503A3 (en) | MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES | |
WO2002002624A3 (en) | B7-like molecules and uses thereof | |
WO2002024891A3 (en) | B7-like molecules and uses thereof | |
WO2001093902A3 (en) | Immunostimulatory rna/dna hybrid molecules | |
WO2005049630A3 (en) | Antisense modulation of kinesin-like 1 expression | |
IL147271A0 (en) | Compounds that bind her2 | |
EP2199299A3 (en) | Antisense modulation of survivin expression | |
WO2003054154A3 (en) | Antisense modulation of mucin 1, transmembrane expression | |
WO2005014814A3 (en) | 5’-and 3’-capped aptamers and uses therefor | |
WO2003053341A3 (en) | Antisense modulation of ship-1 expression | |
WO2002095053A3 (en) | Antisense modulation of src-c expression | |
WO2003052062A3 (en) | Antisense modulation of cd36l1 expression | |
EP1165145A4 (en) | Antisense modulation of mdmx expression | |
WO2003050244A3 (en) | Antisense modulation of g protein-coupled receptor etbr-lp-2 expression | |
WO2003044047A3 (en) | Virulence proteins of the genus yersinia and uses thereof | |
EP1248635A4 (en) | Antisense modulation of glycogen synthase kinase 3 alpha expression | |
EP1448762A4 (en) | Antisense modulation of toll-like receptor 4 expression field of the invention | |
WO2003031576A3 (en) | Antisense modulation of inhibitor-kappa b kinase-gamma expression | |
WO2003050247A3 (en) | Antisense modulation of mhc class ii transactivator expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002365141 Country of ref document: AU |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2463798 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003558124 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047006160 Country of ref document: KR |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/21-21/21, DRAWINGS, REPLACED BY NEW PAGES 1/20-20/20 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002365141 Country of ref document: AU |